Eight years on, Emcure Pharma takes a second shot at IPO


Last Updated: Dec 09, 2022 - 02:50 am 55.6k Views
Listen icon

Pune-based Emcure Pharmaceuticals Ltd is making its second attempt to float an initial public offering (IPO), joining a bunch of healthcare companies to tap into the stock market buoyancy. 

Emcure has filed a draft prospectus with the capital markets regulator Securities and Exchange Board of India for the IPO that includes both primary and secondary share sales.

While the drugmaker aims to raise Rs 1,100 crore by issuing fresh shares in the IPO, its promoters and investor Bain Capital plan to sell a total of 18.16 million shares. Private equity firm Bain alone will sell almost 10 million shares.
Emcure joins a growing list of healthcare services and pharmaceutical companies to float an IPO. Already, companies such as pathology chain Krsnaa Diagnostics Ltd, hospital operator Krishna Institute of Medical Sciences and drugmakers Windlas Biotech Ltd and Glenmark Life Sciences Ltd have gone public this year.

Emcure’s planned IPO comes eight years after Emcure first approached SEBI for its maiden share sale in July 2013. However, the drugmaker eventually scrapped the proposal. 
Emcure makes and sells a wide range of pharmaceutical products across several therapeutic areas. The company claims it is the 12th largest drugmaker in India by revenue and the largest in segments such as gynaecologyand HIV anti virals .The company says it is also developing a Covid-19 vaccine.

Emcure was set up in 1981. It operates 14 manufacturing plants.The company’s consolidated net profit soared to Rs 418.59 crore for the year through March 2021 from Rs 100.61 crore a year earlier. Revenue from operations jumped to Rs 6,056.41 crore from Rs 5,048.55 crore.

Share Market Today


How do you rate this article?

Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

378X91-D3

About the Author


Enjoy 0%* Brokerage with 5paisa
Resend OTP
Please Enter OTP
Mobile No. belongs to

By proceeding, you agree to the T&C.

Latest News
Trust Fintech IPO Subscribed 108.63 times

Trust Fintech IPO is book-built issue of ₹63.45 crores, consisting entirely of fresh issue shares totalling 62.82 lakh. Trust Fintech IPO commenced its subscription period on March 26, 2024, & concludes today, March 28, 2024.

Aspire & Innovative IPO Subscribed 15.17 times

Aspire & Innovative IPO is a book built issue of Rs 21.97 crores. The issue comprises entirely a fresh issue of 40.68 lakh shares. Aspire & Innovative IPO opens for subscription on March 26, 2024, and closes on March 28, 2024. The allotment for the Aspire & Innovative IPO is expected to be finalized on Monday, April 1, 2024.

Blue Pebble IPO Subscribed 56.32 times

Blue Pebble IPO, valued at ₹18.14 crores, comprises fresh issue of 10.8 lakh shares. Commencing subscription on March 26, 2024, Blue Pebble IPO is set to conclude on March 28, 2024. Allotment process is scheduled to be finalized by Monday, April 1, 2024. Following this, IPO is slated to debut on NSE SME, with tentative listing date of Wednesday, April 3, 2024.